Morepen Labs Ignites Hope: Pioneering Resmetirom Set to Transform Fatty Liver Care in India

Morepen Laboratories Ltd will make a major entry into liver disease treatment following clearance by the Central Drugs Standard Control Organization (CDSCO) to carry out bioequivalence (BE) studies for Resmetirom, a novel drug for non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). The development places Morepen among the earliest Indian firms to bring this novel therapy, recently cleared in the US, into the local market.

 

Key Highlights:

Sources: CDSCO, PubMed, Medical Dialogues, Madrigal Pharmaceuticals